Macular Edema Pipeline Review, H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Macular Edema - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Macular Edema - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 7 and 1 respectively.

Companies Mentioned

• ActiveSite Pharmaceuticals Inc
• Coherus BioSciences Inc
• EyeGate Pharmaceuticals Inc
• Lupin Ltd
• Mabion SA
• OMEICOS Therapeutics GmbH
• Promedior Inc
• Taiwan Liposome Company Ltd
• Xbrane Biopharma AB

Key Topics Covered

1. Introduction
2. Report Coverage
3. Macular Edema - Overview
4. Macular Edema - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Products under Development by Companies
8. Macular Edema - Therapeutics Assessment
9. Assessment by Target
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Macular Edema - Companies Involved in Therapeutics Development
14. ActiveSite Pharmaceuticals Inc
15. Coherus BioSciences Inc
16. EyeGate Pharmaceuticals Inc
17. Lupin Ltd
18. Mabion SA
19. OMEICOS Therapeutics GmbH
20. Promedior Inc
21. Taiwan Liposome Company Ltd
22. Xbrane Biopharma AB
23. Macular Edema - Drug Profiles
24. ACX-107 - Drug Profile
25. Product Description
26. Mechanism Of Action
27. R&D Progress
28. aflibercept biosimilar - Drug Profile
29. Product Description
30. Mechanism Of Action
31. R&D Progress
32. ASPPDC-020 - Drug Profile
33. Product Description
34. Mechanism Of Action
35. R&D Progress
36. dexamethasone phosphate - Drug Profile
37. Product Description
38. Mechanism Of Action
39. R&D Progress
40. dexamethasone sodium phosphate SR 1 - Drug Profile
41. Product Description
42. Mechanism Of Action
43. R&D Progress
44. OMT-28 - Drug Profile
45. Product Description
46. Mechanism Of Action
47. R&D Progress
48. PRM-167 - Drug Profile
49. Product Description
50. Mechanism Of Action
51. R&D Progress
52. ranibizumab biosimilar - Drug Profile
53. Product Description
54. Mechanism Of Action
55. R&D Progress
56. ranibizumab biosimilar - Drug Profile
57. Product Description
58. Mechanism Of Action
59. R&D Progress
60. ranibizumab biosimilar - Drug Profile
61. Product Description
62. Mechanism Of Action
63. R&D Progress
64. Macular Edema - Dormant Projects
65. Macular Edema - Discontinued Products
66. Macular Edema - Product Development Milestones
67. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/dzgljn/macular_edema?w=4